Barghash R, Gemmati D, Awad A, Elbakry M, Tisato V, Awad K
Molecules. 2024; 29(23.
PMID: 39683724
PMC: 11643501.
DOI: 10.3390/molecules29235564.
El-Saadony M, Saad A, Korma S, Salem H, Abd El-Mageed T, Sami Alkafaas S
Front Immunol. 2024; 15:1277074.
PMID: 38915405
PMC: 11194342.
DOI: 10.3389/fimmu.2024.1277074.
Yang J, Wu S, Li X, Wang X, Zhang X, Hou L
Infect Dis Model. 2024; 9(3):975-994.
PMID: 38881537
PMC: 11180336.
DOI: 10.1016/j.idm.2024.05.004.
Zargari F, Mohammadi M, Nowroozi A, Morowvat M, Nakhaei E, Rezagholi F
Recent Pat Biotechnol. 2024; 18(4):316-331.
PMID: 38817009
DOI: 10.2174/0118722083246773231108045238.
Hussein H, Thabet A, Wardany A, El-Adly A, Ali M, Hassan M
Virol J. 2024; 21(1):75.
PMID: 38539202
PMC: 10967059.
DOI: 10.1186/s12985-024-02342-w.
Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression.
Kurniawan A, Hariyanto T
Narra J. 2024; 3(1):e102.
PMID: 38450034
PMC: 10914142.
DOI: 10.52225/narra.v3i1.102.
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Sharun K, Tiwari R, Yatoo M, Natesan S, Megawati D, Singh K
Narra J. 2024; 2(3):e92.
PMID: 38449903
PMC: 10914132.
DOI: 10.52225/narra.v2i3.92.
anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation - Targeting Mpro and pan-coronavirus post-fusion Spike protein.
Mandal S, Rehman M, Katyal A, Rajvanshi K, Kannan M, Garg M
J Tradit Complement Med. 2024; 14(1):55-69.
PMID: 38223813
PMC: 10785248.
DOI: 10.1016/j.jtcme.2023.07.004.
Implications of empirical administration of caspofungin in COVID-19 complicated fungal infections.
Itoh K, Tsutani H, Mitsuke Y, Iwasaki H
Front Cell Infect Microbiol. 2023; 13:1269543.
PMID: 38076460
PMC: 10703040.
DOI: 10.3389/fcimb.2023.1269543.
Galactoside-Based Molecule Enhanced Antimicrobial Activity through Acyl Moiety Incorporation: Synthesis and In Silico Exploration for Therapeutic Target.
Ahmmed F, Al-Mijalli S, Abdallah E, Eissa I, Ali F, Bhat A
Pharmaceuticals (Basel). 2023; 16(7).
PMID: 37513910
PMC: 10385442.
DOI: 10.3390/ph16070998.
An overview on medicinal plants used for combating coronavirus: Current potentials and challenges.
Abou Baker D, Hassan E, El Gengaihi S
J Agric Food Res. 2023; 13:100632.
PMID: 37251276
PMC: 10198795.
DOI: 10.1016/j.jafr.2023.100632.
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?.
Hashemian S, Sheida A, Taghizadieh M, Memar M, Hamblin M, Baghi H
Biomed Pharmacother. 2023; 162:114367.
PMID: 37018987
PMC: 9899776.
DOI: 10.1016/j.biopha.2023.114367.
Insights into COVID-19-associated critical illness: a narrative review.
Dong M, Chen S, Lin S, Han F, Zhong M
Ann Transl Med. 2023; 11(5):220.
PMID: 37007577
PMC: 10061462.
DOI: 10.21037/atm-22-2541.
Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (M) using molecular docking and deep learning methods.
Hossain A, Rahman M, Rahman M, Nasirujjaman K, Matin M, Faruqe M
Comput Biol Med. 2023; 157:106785.
PMID: 36931201
PMC: 10008098.
DOI: 10.1016/j.compbiomed.2023.106785.
Paving New Roads Using as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology.
Atoum M, Padma K, Don K
Iran J Pharm Res. 2023; 21(1):e131577.
PMID: 36915406
PMC: 10007998.
DOI: 10.5812/ijpr-131577.
In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from .
Mengist H, Khalid Z, Adane F
Adv Appl Bioinform Chem. 2023; 16:1-13.
PMID: 36699952
PMC: 9868284.
DOI: 10.2147/AABC.S393084.
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.
Malchair P, Giol J, Garcia V, Rodriguez O, Ruibal J, Zarauza A
Clin Infect Dis. 2023; 76(10):1784-1792.
PMID: 36610464
PMC: 10209439.
DOI: 10.1093/cid/ciac984.
Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.
Liu X, Shi J, Wang D, Su Y, Xing Z, Sun F
Clin Drug Investig. 2022; 43(1):13-22.
PMID: 36462104
PMC: 9734822.
DOI: 10.1007/s40261-022-01231-w.
Potential SARS-CoV-2 RdRp inhibitors of cytidine derivatives: Molecular docking, molecular dynamic simulations, ADMET, and POM analyses for the identification of pharmacophore sites.
Kawsar S, Hosen M, Ahmad S, El Bakri Y, Laaroussi H, Hadda T
PLoS One. 2022; 17(11):e0273256.
PMID: 36441684
PMC: 9704642.
DOI: 10.1371/journal.pone.0273256.
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.
Gupta Y, Savytskyi O, Coban M, Venugopal A, Pleqi V, Weber C
Mol Aspects Med. 2022; 91:101151.
PMID: 36371228
PMC: 9613808.
DOI: 10.1016/j.mam.2022.101151.
